Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept

[1]  H. Bliddal,et al.  Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission. , 2020, Rheumatology.

[2]  A. H. M. van der Helm-van Mil,et al.  DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability , 2020, RMD Open.

[3]  P. Maffia,et al.  Molecular imaging of inflammation - Current and emerging technologies for diagnosis and treatment. , 2020, Pharmacology & therapeutics.

[4]  J. Baker,et al.  Sex Differences in the Achievement of Remission and Low Disease Activity in Rheumatoid Arthritis , 2020, Arthritis care & research.

[5]  J. Smolen,et al.  Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis. , 2019, Rheumatology.

[6]  D. Furst,et al.  Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study , 2019, RMD Open.

[7]  L. Terslev,et al.  Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors , 2018, Rheumatology.

[8]  A. Barton,et al.  Rheumatoid arthritis , 2018, Nature Reviews Disease Primers.

[9]  Publisher's Note , 2018, Anaesthesia.

[10]  P. Emery,et al.  Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis , 2017, Annals of the rheumatic diseases.

[11]  E. Sasso,et al.  A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes , 2017, Rheumatology.

[12]  P. Emery,et al.  Development and validation of rheumatoid arthritis magnetic resonance imaging inflammation thresholds associated with lack of damage progression. , 2017, Clinical and experimental rheumatology.

[13]  R. Landewé,et al.  Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis , 2017, RMD Open.

[14]  M. Dougados,et al.  2016 update of the EULAR recommendations for the management of early arthritis , 2016, Annals of the rheumatic diseases.

[15]  P. Emery,et al.  Relationship of patient-reported outcomes with MRI measures in rheumatoid arthritis , 2016, Annals of the rheumatic diseases.

[16]  P. Conaghan,et al.  FRI0513 Validating Mri-Detected Inflammation Thresholds Predictive of Structural Damage Progression in Patients with Rheumatoid Arthritis in A Randomized Placebo-Controlled Trial , 2016 .

[17]  J. Smolen.  Treat-to-target as an approach in inflammatory arthritis , 2016, Current opinion in rheumatology.

[18]  L. March,et al.  Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set , 2016, RMD Open.

[19]  G. Ferraccioli,et al.  Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission , 2016, Arthritis Research & Therapy.

[20]  Raveendhara R. Bannuru,et al.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis care & research.

[21]  W. Robinson,et al.  Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial , 2015, Annals of the rheumatic diseases.

[22]  E. Naredo,et al.  Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis. , 2015, Rheumatology.

[23]  M. Dougados,et al.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force , 2015, Annals of the rheumatic diseases.

[24]  D. Furst,et al.  Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period , 2014, Annals of the rheumatic diseases.

[25]  T. Iwamoto,et al.  Prediction of Relapse After Discontinuation of Biologic Agents by Ultrasonographic Assessment in Patients With Rheumatoid Arthritis in Clinical Remission: High Predictive Values of Total Gray‐Scale and Power Doppler Scores That Represent Residual Synovial Inflammation Before Discontinuation , 2014, Arthritis care & research.

[26]  Andrew K. Brown,et al.  Determining a Magnetic Resonance Imaging Inflammatory Activity Acceptable State Without Subsequent Radiographic Progression in Rheumatoid Arthritis: Results from a Followup MRI Study of 254 Patients in Clinical Remission or Low Disease Activity , 2014, The Journal of Rheumatology.

[27]  P. Emery,et al.  Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial , 2013, Annals of the rheumatic diseases.

[28]  P. Conaghan,et al.  Imaging tools in rheumatoid arthritis: ultrasound vs magnetic resonance imaging. , 2012, Rheumatology.

[29]  Mahboob Rahman,et al.  Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial , 2011, Annals of the rheumatic diseases.

[30]  David T Felson,et al.  UvA-DARE (Digital Academic Repository) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials , 2011 .

[31]  B. Dijkmans,et al.  Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study , 2010, Annals of the rheumatic diseases.

[32]  A. Silman,et al.  Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .

[33]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.

[34]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[35]  P. Emery,et al.  Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? , 2010, Annals of the rheumatic diseases.

[36]  C. Peterfy,et al.  An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[37]  C. Peterfy,et al.  Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. , 2006, Arthritis and rheumatism.

[38]  P. V. van Riel,et al.  Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. , 2004, Rheumatology.

[39]  Paul Bird,et al.  OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. , 2003, The Journal of rheumatology.

[40]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .